Europe Pneumococcal Vaccine Market Size Worth USD 2.9 Billion By 2032 | CAGR: 5.7%

The Europe pneumococcal vaccine market size is expected to reach USD 2.9 billion by 2032, according to a new study by Polaris Market Research. The report “Europe Pneumococcal Vaccine Market Size, Share, Trends, Industry Analysis Report: By Type (Pneumococcal Conjugate Vaccines and Pneumococcal Polysaccharide Vaccines), Product, End User, and Country – Market Forecast, 2023–2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Pneumococcal vaccination programs play a crucial role in preventing diseases caused by streptococcus pneumoniae, which lead to serious health issues such as pneumonia, meningitis, and sepsis. Most European countries include PCVs in their national immunization programs (NIPs), targeting primarily children under five and older adults.

The introduction of higher-valent pneumococcal conjugate vaccines (PCVs) is estimated to drive the Europe pneumococcal vaccine market in the coming years. Higher-valent PCVs protect against a greater number of pneumococcal serotypes, reducing the risk of disease from strains that were previously not covered. This increased coverage is appealing to healthcare providers and patients alike, thereby boosting demand.

The growing geriatric population in Europe is projected to propel the Europe pneumococcal vaccine market during the forecast period. Pneumococcal diseases have higher morbidity and mortality rates among the elderly. Vaccination is essential for reducing these health risks, leading to increased demand. Thus, as the senior population increases in Europe, the demand for pneumococcal vaccines increases. For instance, the population of older people aged 65 years and above in the EU is estimated to increase significantly, rising from 90.5 million at the start of 2019 to reach 129.8 million by 2050.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/europe-pneumococcal-vaccine-market/request-for-sample

The collaborations between public health authorities and private vaccine manufacturers are projected to fuel market growth as this collaboration enhances distribution and accessibility, supporting market growth.

The growing prevalence of pneumonia in Europe propels the demand for pneumococcal vaccines. Higher pneumonia prevalence often leads health authorities to strengthen recommendations for pneumococcal vaccination, especially for vulnerable populations, which increases uptake. According to the National Library of Medicine, pneumonia is responsible for ∼230,000 deaths in Europe each year.

Increased public awareness and education about the importance of vaccinations and the risks of pneumococcal diseases contribute to higher vaccination rates, which ultimately boost demand for pneumococcal vaccines.

Europe Pneumococcal Vaccine Market Report Highlights

• Based on type, the pneumococcal conjugate vaccines segment dominated the Europe pneumococcal vaccine market in 2023 due to their effectiveness in preventing a broader range of pneumococcal diseases and advances in vaccine technology.
• In terms of end users, the public sector segment accounted for a larger market share in 2023, owing to the rising funding from international health organizations.
• The UK dominated the market in Europe in 2023, owing to a well-established immunization program, a growing elderly population, and ongoing research and advancements in vaccine technology.
• The market in Germany is projected to register the fastest growth during the forecast period, attributable to the robust healthcare system and the growing awareness of the importance of vaccinations, particularly among healthcare professionals and the general public.
• Astellas Pharma Inc., CSL Ltd, GSK Plc, Merck & Co. Inc., Panacea Biotech Ltd, GPN Vaccines, SK Bioscience, Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd, Talley Group Ltd, and Walvax Biotechnology Co. Ltd. are among the global market players.

Polaris Market Research has segmented the Europe pneumococcal vaccine market report on the basis of type, product, end user, and country:

By Type Outlook (Revenue – USD Billion, 2019–2032)

• Pneumococcal Conjugate Vaccines
• Pneumococcal Polysaccharide Vaccines

By Product Outlook (Revenue – USD Billion, 2019–2032)

• Prevnar 13
• Synflorix
• Pneumovax 23
• VAXNEUVANCE
• PNEUMOSIL
• Other

By End User Outlook (Revenue – USD Billion, 2019–2032)

• Public Sector
• Private Sector

By Country Outlook (Revenue – USD Billion, 2019–2032)

• France
• Germany
• UK
• Italy
• Netherlands
• Spain
• Russia
• Rest of Europe

Europe Pneumococcal Vaccine Market Report Scope